Exact Sciences CorpNASDAQ:EXAS
- LAST PRICE61.0300
- TODAY'S CHANGE (%)-0.3800 (-0.6188%)
- Bid / Lots60.8600/ 4
- Ask / Lots61.1100/ 4
- Open / Previous Close61.0000 / 61.4100
- Day Range
- 52 Week Range
- Volume269,993
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | EXAS |
|---|---|---|
| 09:32 ET | 29775 | 61.55 |
| 09:34 ET | 47407 | 61.34 |
| 09:36 ET | 4918 | 61.28 |
| 09:38 ET | 3700 | 61.5591 |
| 09:39 ET | 1600 | 61.48 |
| 09:41 ET | 5315 | 61.3625 |
| 09:43 ET | 1200 | 61.22 |
| 09:45 ET | 2395 | 61.03 |
| 09:48 ET | 9362 | 61.1 |
| 09:50 ET | 76802 | 61.345 |
| 09:52 ET | 18707 | 61.025 |
| 09:54 ET | 3573 | 61.2 |
| 09:56 ET | 1500 | 61.215 |
| 09:57 ET | 962 | 61.225 |
| 09:59 ET | 6129 | 61.11 |
| 10:01 ET | 19844 | 61.03 |
Yesterday
May 1, 2024
Exact Sciences to Participate in May Investor Conference, from 6:00AM ET on Wednesday May 01, 2024 by Dow Jones
6:00AM ET on Wednesday May 01, 2024 by Dow Jones
Apr 15, 2024
DJ Exact Sciences Taps Aaron Bloomer as Finance Chief, from 6:19AM ET on Monday Apr 15, 2024 by Dow Jones
6:19AM ET on Monday Apr 15, 2024 by Dow JonesExact Sciences Names Aaron Bloomer as New Chief Financial Officer, from 6:00AM ET on Monday Apr 15, 2024 by Dow Jones
6:00AM ET on Monday Apr 15, 2024 by Dow Jones*DJ Exact Sciences Names Aaron Bloomer As New Chief Financial Officer >EXAS, from 6:00AM ET on Monday Apr 15, 2024 by Dow Jones
6:00AM ET on Monday Apr 15, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Exact Sciences Corp | 11.3B | -53.8x | --- |
United Therapeutics Corp | 11.8B | 12.6x | +8.22% |
Biomarin Pharmaceutical Inc | 15.7B | 78.1x | --- |
Medpace Holdings Inc | 12.5B | 40.8x | +35.10% |
Qiagen NV | 9.5B | 28.3x | +12.66% |
Beigene Ltd | 17.7B | -19.4x | --- |
Company Information
Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening, MCED Test Development and MRD Test Development. The Company’s products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, and OncoExTra Test. The Company’s flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
Contact Information
- Headquarters
- 5505 Endeavor LaneMADISON, WI, United States 53719
- Phone
- 608-284-5700
- Fax
- 608-284-5701
Executives
- Chairman of the Board, President, Chief Executive Officer
- Kevin Conroy
- Chief Financial Officer, Chief Operating Officer, Executive Vice President
- Jeffrey Elliott
- Executive Vice President - Finance
- Aaron Bloomer
- Executive Vice President - Human Resources
- Sarah Condella
- Senior Vice President, General Counsel, Company Secretary
- James Herriott
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $11.3B |
|---|---|
Revenue (TTM) | $2.5B |
Shares Outstanding | 183.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.33 |
EPS | $-1.14 |
Book Value | $17.34 |
P/E Ratio | -53.8x |
Price/Sales (TTM) | 4.5 |
Price/Cash Flow (TTM) | 4,591.4x |
Operating Margin | -8.19% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
